Physician profile
Cara Lenz
NPI 1942427810
$4,896.94
in general payments reported to CMS, 2019-2025
33 companies · $778 in 2025
The $778 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $313 · 2021: $359 · 2022: $593 · 2023: $1,962 · 2024: $610 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,093 · Travel and Lodging: $1,257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,092.59 |
| Travel and Lodging | $1,257.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $1,619.26 | 2022-2025 | Acessa Provu System, Novasure, Myosure Tissue Removal Device |
| Abbvie INC. | $487.23 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $313.62 | 2022-2025 | |
| Sage Therapeutics, LLC | $253.89 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $236.21 | 2019-2024 | |
| Therapeuticsmd, INC. | $208.82 | 2019-2022 | |
| Novo Nordisk INC | $199.69 | 2020-2023 | Wegovy |
| Mylan Pharmaceuticals INC. | $169.75 | 2020-2022 | |
| Baxter Healthcare | $140.22 | 2024-2025 | Perclot, Tisseel |
| Astellas Pharma US INC | $135.62 | 2019-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $122.31 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $122.08 | 2023-2025 | Myfembree |
| Coopersurgical, INC. | $114.37 | 2022-2025 | Ally II Ups, Advincula Delineator Uterine Manipulator |
| Myriad Women'S Health, INC. | $100.98 | 2023 | Myrisk |
| Biogen, INC. | $97.00 | 2025 | Zurzuvae |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Applied Medical Resources Corporation | $82.16 | 2022 | |
| Ethicon US, LLC | $76.07 | 2022-2025 | Vistaseal, Stratafix |
| Shield Therapeutics INC | $71.24 | 2023-2024 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $54.01 | 2022-2023 | Trintellix |
| Duchesnay USA Incorporated | $52.69 | 2019 | |
| Myovant Sciences INC. | $37.72 | 2022 | |
| Merck Sharp & Dohme LLC | $32.49 | 2022-2024 | Gardasil 9, Gardasil |
| Lupin INC. | $22.95 | 2019-2020 | |
| Scynexis, INC. | $20.68 | 2022 | |
| Radius Health, INC. | $17.58 | 2020 | |
| Axsome Therapeutics, INC. | $16.45 | 2022 | |
| Exeltis, USA INC. | $14.91 | 2024 | Slynd |
| Millicent US INC | $14.28 | 2024 | Intrarosa |
| Meditrina | $13.80 | 2024 | |
| Endo Pharmaceuticals INC. | $13.22 | 2019 | |
| Mission Pharmacal Company | $13.08 | 2020 | |
| Daiichi Sankyo INC. | $12.93 | 2019 | |
| Evofem Biosciences, INC. | $9.63 | 2025 | Phexxi, Solosec, Phexx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Lenz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.